Aims: The approval of extended release injectable naltrexone suspension (XR-NTX) has introduced a new option for treating opioid addiction, but the absence of physiological opioid dependence is a necessary and challenging first step for starting therapy. Outpatient detoxification gives poor results and inpatient detoxification is either unavailable or too brief for the physiological effects of opioids to resolve. We summarize findings from an open label study that tested whether the transition from opioid addiction to XR-NTX can be safely and effectively performed in an office-based setting using very low dose oral naltrexone and buprenorphine/naloxone (NTX/BUP). (Source: Drug and Alcohol Dependence)